|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NXF1 |
Gene summary for NXF1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NXF1 | Gene ID | 10482 |
| Gene name | nuclear RNA export factor 1 | |
| Gene Alias | MEX67 | |
| Cytomap | 11q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0006403 | UniProtAcc | Q59E96 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10482 | NXF1 | P26T-E | Human | Esophagus | ESCC | 3.28e-09 | 3.89e-02 | 0.1276 |
| 10482 | NXF1 | P27T-E | Human | Esophagus | ESCC | 1.07e-13 | 1.40e-01 | 0.1055 |
| 10482 | NXF1 | P28T-E | Human | Esophagus | ESCC | 3.62e-33 | 5.90e-01 | 0.1149 |
| 10482 | NXF1 | P30T-E | Human | Esophagus | ESCC | 2.86e-10 | 6.19e-01 | 0.137 |
| 10482 | NXF1 | P31T-E | Human | Esophagus | ESCC | 1.12e-19 | 1.32e-01 | 0.1251 |
| 10482 | NXF1 | P32T-E | Human | Esophagus | ESCC | 6.01e-12 | 1.64e-01 | 0.1666 |
| 10482 | NXF1 | P36T-E | Human | Esophagus | ESCC | 4.11e-08 | 3.51e-01 | 0.1187 |
| 10482 | NXF1 | P37T-E | Human | Esophagus | ESCC | 1.37e-14 | 7.86e-02 | 0.1371 |
| 10482 | NXF1 | P39T-E | Human | Esophagus | ESCC | 2.63e-22 | 1.24e-02 | 0.0894 |
| 10482 | NXF1 | P42T-E | Human | Esophagus | ESCC | 3.31e-13 | 4.88e-01 | 0.1175 |
| 10482 | NXF1 | P44T-E | Human | Esophagus | ESCC | 8.01e-09 | 1.21e-01 | 0.1096 |
| 10482 | NXF1 | P47T-E | Human | Esophagus | ESCC | 2.50e-15 | 2.37e-01 | 0.1067 |
| 10482 | NXF1 | P48T-E | Human | Esophagus | ESCC | 1.65e-16 | 3.24e-01 | 0.0959 |
| 10482 | NXF1 | P49T-E | Human | Esophagus | ESCC | 6.99e-07 | 1.05e+00 | 0.1768 |
| 10482 | NXF1 | P52T-E | Human | Esophagus | ESCC | 2.87e-18 | 2.47e-01 | 0.1555 |
| 10482 | NXF1 | P54T-E | Human | Esophagus | ESCC | 5.69e-13 | 3.42e-01 | 0.0975 |
| 10482 | NXF1 | P56T-E | Human | Esophagus | ESCC | 1.52e-03 | 1.05e+00 | 0.1613 |
| 10482 | NXF1 | P57T-E | Human | Esophagus | ESCC | 5.82e-17 | 2.35e-01 | 0.0926 |
| 10482 | NXF1 | P61T-E | Human | Esophagus | ESCC | 3.59e-16 | 4.35e-01 | 0.099 |
| 10482 | NXF1 | P62T-E | Human | Esophagus | ESCC | 2.59e-31 | 6.40e-01 | 0.1302 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006913 | Colorectum | AD | nucleocytoplasmic transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
| GO:0051169 | Colorectum | AD | nuclear transport | 102/3918 | 301/18723 | 1.00e-07 | 4.85e-06 | 102 |
| GO:0006403 | Colorectum | AD | RNA localization | 71/3918 | 201/18723 | 1.54e-06 | 4.76e-05 | 71 |
| GO:0051236 | Colorectum | AD | establishment of RNA localization | 58/3918 | 166/18723 | 1.95e-05 | 4.01e-04 | 58 |
| GO:0015931 | Colorectum | AD | nucleobase-containing compound transport | 73/3918 | 222/18723 | 2.02e-05 | 4.10e-04 | 73 |
| GO:0050657 | Colorectum | AD | nucleic acid transport | 57/3918 | 163/18723 | 2.22e-05 | 4.39e-04 | 57 |
| GO:0050658 | Colorectum | AD | RNA transport | 57/3918 | 163/18723 | 2.22e-05 | 4.39e-04 | 57 |
| GO:0051168 | Colorectum | AD | nuclear export | 53/3918 | 154/18723 | 6.89e-05 | 1.11e-03 | 53 |
| GO:0051028 | Colorectum | AD | mRNA transport | 42/3918 | 130/18723 | 1.57e-03 | 1.32e-02 | 42 |
| GO:00069131 | Colorectum | SER | nucleocytoplasmic transport | 77/2897 | 301/18723 | 3.39e-06 | 1.32e-04 | 77 |
| GO:00511691 | Colorectum | SER | nuclear transport | 77/2897 | 301/18723 | 3.39e-06 | 1.32e-04 | 77 |
| GO:00064031 | Colorectum | SER | RNA localization | 53/2897 | 201/18723 | 4.51e-05 | 1.13e-03 | 53 |
| GO:00511681 | Colorectum | SER | nuclear export | 42/2897 | 154/18723 | 1.19e-04 | 2.46e-03 | 42 |
| GO:00159311 | Colorectum | SER | nucleobase-containing compound transport | 54/2897 | 222/18723 | 3.65e-04 | 5.67e-03 | 54 |
| GO:00512361 | Colorectum | SER | establishment of RNA localization | 42/2897 | 166/18723 | 6.70e-04 | 8.96e-03 | 42 |
| GO:00506571 | Colorectum | SER | nucleic acid transport | 41/2897 | 163/18723 | 8.74e-04 | 1.06e-02 | 41 |
| GO:00506581 | Colorectum | SER | RNA transport | 41/2897 | 163/18723 | 8.74e-04 | 1.06e-02 | 41 |
| GO:00069132 | Colorectum | MSS | nucleocytoplasmic transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
| GO:00511692 | Colorectum | MSS | nuclear transport | 99/3467 | 301/18723 | 1.35e-09 | 1.03e-07 | 99 |
| GO:00064032 | Colorectum | MSS | RNA localization | 69/3467 | 201/18723 | 6.33e-08 | 3.26e-06 | 69 |
| Page: 1 2 3 4 5 6 7 8 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05014 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
| hsa03015 | Colorectum | AD | mRNA surveillance pathway | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
| hsa050141 | Colorectum | AD | Amyotrophic lateral sclerosis | 164/2092 | 364/8465 | 4.28e-18 | 1.27e-16 | 8.09e-17 | 164 |
| hsa030151 | Colorectum | AD | mRNA surveillance pathway | 35/2092 | 97/8465 | 7.95e-03 | 3.13e-02 | 2.00e-02 | 35 |
| hsa050142 | Colorectum | SER | Amyotrophic lateral sclerosis | 138/1580 | 364/8465 | 9.89e-19 | 2.99e-17 | 2.17e-17 | 138 |
| hsa050143 | Colorectum | SER | Amyotrophic lateral sclerosis | 138/1580 | 364/8465 | 9.89e-19 | 2.99e-17 | 2.17e-17 | 138 |
| hsa050144 | Colorectum | MSS | Amyotrophic lateral sclerosis | 156/1875 | 364/8465 | 1.43e-19 | 4.62e-18 | 2.83e-18 | 156 |
| hsa050145 | Colorectum | MSS | Amyotrophic lateral sclerosis | 156/1875 | 364/8465 | 1.43e-19 | 4.62e-18 | 2.83e-18 | 156 |
| hsa050146 | Colorectum | MSI-H | Amyotrophic lateral sclerosis | 95/797 | 364/8465 | 2.31e-21 | 1.50e-19 | 1.26e-19 | 95 |
| hsa050147 | Colorectum | MSI-H | Amyotrophic lateral sclerosis | 95/797 | 364/8465 | 2.31e-21 | 1.50e-19 | 1.26e-19 | 95 |
| hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa0301321 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
| hsa0516425 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
| hsa0301524 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
| hsa0301331 | Esophagus | ESCC | Nucleocytoplasmic transport | 89/4205 | 108/8465 | 1.20e-12 | 2.37e-11 | 1.21e-11 | 89 |
| hsa0516435 | Esophagus | ESCC | Influenza A | 122/4205 | 171/8465 | 5.01e-09 | 4.79e-08 | 2.45e-08 | 122 |
| hsa0301534 | Esophagus | ESCC | mRNA surveillance pathway | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
| hsa0501414 | Liver | Cirrhotic | Amyotrophic lateral sclerosis | 187/2530 | 364/8465 | 1.56e-18 | 6.50e-17 | 4.01e-17 | 187 |
| hsa030154 | Liver | Cirrhotic | mRNA surveillance pathway | 46/2530 | 97/8465 | 1.92e-04 | 1.30e-03 | 8.03e-04 | 46 |
| Page: 1 2 3 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NXF1 | SNV | Missense_Mutation | rs376614748 | c.245N>A | p.Arg82Gln | p.R82Q | Q9UBU9 | protein_coding | deleterious(0.04) | benign(0.161) | TCGA-3C-AALK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
| NXF1 | SNV | Missense_Mutation | c.1152G>C | p.Lys384Asn | p.K384N | Q9UBU9 | protein_coding | deleterious(0) | probably_damaging(0.932) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NXF1 | SNV | Missense_Mutation | rs775505140 | c.1571A>G | p.Asn524Ser | p.N524S | Q9UBU9 | protein_coding | tolerated(0.38) | benign(0.003) | TCGA-A8-A08P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
| NXF1 | SNV | Missense_Mutation | rs369101376 | c.1112C>T | p.Pro371Leu | p.P371L | Q9UBU9 | protein_coding | tolerated(0.11) | probably_damaging(0.993) | TCGA-A8-A09C-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NXF1 | SNV | Missense_Mutation | c.668C>G | p.Ser223Cys | p.S223C | Q9UBU9 | protein_coding | deleterious(0.03) | benign(0.306) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NXF1 | SNV | Missense_Mutation | novel | c.986N>C | p.Asp329Ala | p.D329A | Q9UBU9 | protein_coding | tolerated(0.14) | benign(0.007) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| NXF1 | SNV | Missense_Mutation | c.172N>A | p.Asp58Asn | p.D58N | Q9UBU9 | protein_coding | tolerated(0.75) | probably_damaging(0.914) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| NXF1 | SNV | Missense_Mutation | novel | c.1768N>G | p.Gln590Glu | p.Q590E | Q9UBU9 | protein_coding | tolerated(0.49) | benign(0.02) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| NXF1 | SNV | Missense_Mutation | novel | c.1756N>G | p.Gln586Glu | p.Q586E | Q9UBU9 | protein_coding | deleterious(0.03) | benign(0.179) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NXF1 | SNV | Missense_Mutation | c.250N>A | p.Asp84Asn | p.D84N | Q9UBU9 | protein_coding | tolerated(0.49) | benign(0.014) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |